Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device.

H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of ...

Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat ...

Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...

On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment. Read why I upgrade NVCR stock from buy ...

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...

Stock futures traded mildly to the upside Wednesday and tech shares looked set for a slight rebound following a sharp slump ...

S&P 500 and Nasdaq 100 futures steady amid tech losses. Morgan Stanley beats Q3 estimates, up 3%, and Cisco climbs 2% on AI ...

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.

NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in ...

The US Food and Drug Administration (FDA) has approved Novocure's Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or ...